Quarterly ResultMay 13, 2026, 04:13 PM
TELA Bio Q1 Revenue $19.06M; Net Loss Widens to $12.27M
AI Summary
TELA Bio reported a 2.9% increase in Q1 2026 revenue to $19.06 million, up from $18.52 million in the prior year. However, the company's net loss widened to $12.27 million from $11.26 million, and it transitioned from positive stockholders' equity to a deficit of $5.20 million. Cash and cash equivalents decreased significantly, and net cash used in operating activities increased. The company continues to incur recurring losses and negative cash flows.
Key Highlights
- Q1 2026 revenue increased 2.9% to $19.06 million from $18.52 million year-over-year.
- Net loss widened to $12.27 million in Q1 2026, compared to $11.26 million in Q1 2025.
- Stockholders' equity shifted to a deficit of $5.20 million from positive $6.31 million.
- Cash and cash equivalents decreased to $39.54 million from $50.85 million since Dec 31, 2025.
- Net cash used in operating activities increased to $11.17 million from $9.73 million.
- OviTex product revenue grew 4.2% to $12.62 million; OviTex PRS revenue declined 2.7% to $5.88 million.
- Sales outside the U.S. increased 42.3% to $3.7 million.
- Long-term debt stood at $55.87 million, primarily from the $60.0 million Perceptive Term Loan.